Updates on Aflibercept Biosimilar Approvals and BPCIA Litigation
Federal Circuit Dismisses Appeals in Regeneron v. Mylan (Aflibercept) BPCIA Litigation
DOJ Files False Claims Act Complaint Against Regeneron, Alleging Fraudulent Eylea Drug Pricing
Post-Trial Updates on Regeneron v. Mylan (Aflibercept) BPCIA Litigation
Celltrion and Samsung File IPR Petitions on Aflibercept Patents
Celltrion Files IPR Petition on Aflibercept Patent
Outlook Therapeutics Re-Submits Its Ophthalmic Bevacizumab BLA
Amgen Announces Positive Top-Line Results from Phase 3 Study of Eculizumab Biosimilar
Alvotech Announces Positive Results from a Pharmacokinetic Similarity Study for Ustekinumab Biosimilar
Subscribe: Subscribe via RSS
Blogs
Firm/Org